Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs

LONDON, December 3 - Chiltern International Limited (Chiltern), a global clinical research
organization (CRO) providing clinical development and staffing services in
Europe, the Americas and Asia, today announces the appointment of Dr. Sharon
Moore as Executive Vice President, Global Quality & Medical Affairs. Dr.
Moore is based at Chiltern's Bristol, Tennessee, USA office.

Dr. Moore is a physician with 15 years of industry experience. Prior to
joining Chiltern, Sharon served as a pharmacovigilance physician and
practiced medicine, served as an investigator, was a member of an
Institutional Review Board and authored several publications. She joined
CTMS, a US CRO, in 1998. Sharon has served with Chiltern since the
acquisition of CTMS in 2007 as Global Head of Quality Assurance and Executive
Director, Medical Affairs. Sharon has Masters in Public Health (MPH) and
Business Administration (MBA), holds an active medical license, and is a
Certified Physician Investigator (CPI) through the Academy of Pharmaceutical
Physicians and Investigators (APPI).

"I am delighted to appoint Dr. Moore to lead our global quality and
medical functions and to have her join our Group Executive Board," stated
Glenn Kerkhof, CEO of Chiltern. This is a key scientific appointment and Dr.
Moore brings a wealth of experience which will enhance our operational
delivery and consultative approach for our clients."

Dr. Moore commented, "I am excited about the opportunity to represent our
global QA, Medical and Pharmacovigilance functions. We work in a dynamic
environment with increasing complexity of clinical trials and growing
importance of safety surveillance. Our teams are working to strengthen our
services and to prepare for new medical developments."

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical Contract
Research Organization with extensive experience conducting and staffing
international Phase I to Phase IV clinical trials across a broad range of
therapeutic areas for a wide variety of clients. Chiltern has conducted
trials in more than 40 countries and employs 1,400 people in 28 countries.
Chiltern provides Early Phase, Global Clinical Development, Late Phase,
Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services.
Further information: www.chiltern.com.

    For More Information:

    Natalie Chong, Chiltern International  Sue Ojanen, Chiltern International
     Ltd.                                   Inc.
    171 Bath Road                          1241 Volunteer Parkway
    Slough, Berkshire SL1 4AA, UK          Bristol, TN 37620, USA
    Tel:  +44-(0)-1753-512-000             Tel:  +1-423-968-9533
    Email: natalie.chong@chiltern.com      Email: sue.ojanen@chiltern.com

Natalie Chong of Chiltern International Ltd., +44-(0)-1753-512-000, natalie.chong at chiltern.com, or Sue Ojanen of Chiltern International Inc., +1-423-968-9533, sue.ojanen at chiltern.com